Brief: Tenax Therapeutics Announces FDA Clearance Of Ind For Tnx-103 (Oral Levosimendan)

Tenax Therapeutics

13/11/2023 14:48

Nov 13 (Reuters) - Tenax Therapeutics Inc  TENX.O :
    * TENAX THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR
TNX-103
(ORAL LEVOSIMENDAN) FOR THE TREATMENT OF PULMONARY HYPERTENSION
WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFPEF), 
INITIATION OF PHASE 3 SITES EXPECTED 2023
    * TENAX THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR
TNX-103
(ORAL LEVOSIMENDAN) FOR THE TREATMENT OF PULMONARY HYPERTENSION
WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFPEF), 
INITIATION OF PHASE 3 SITES EXPECTED 2023

Source text for Eikon:  ID:nGNX8MGLS7 
Further company coverage:  TENX.O 

 ((Reuters.Briefs@thomsonreuters.com;))